Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio (PALI) has secured clearance from the NMPA in China to initiate a Phase 3 clinical trial for LB1148, aimed at expediting bowel function recovery in patients undergoing abdominal surgery. This follows recent FDA clearance for the same Phase 3 study in the U.S. LB1148, an oral serine protease inhibitor, showed statistically significant results in a previous Phase 2 trial. Newsoara Biopharma will fully fund the Phase 3 program in China and trigger milestone payments upon achieving specific goals.

Palisade Bio (Nasdaq: PALI) is set to commence a Phase 3 clinical trial for its lead product, LB1148, aimed at enhancing postoperative bowel function, in Q2 2022. The therapy is designed to mitigate gastrointestinal complications by inhibiting digestive proteases during surgery, potentially reducing hospital stays and abdominal adhesions. A recent study demonstrated a 72% decrease in adhesion incidence among patients treated with LB1148. The FDA granted Fast Track designation for LB1148, reflecting its importance in surgical recovery.

Palisade Bio (Nasdaq: PALI) will host a virtual investor management and KOL roundtable on May 3, 2022, at 10:00 AM ET. Management team members, including CEO Tom Hallam, CMO Michael Dawson, and VP Robert McRae, will participate alongside Key Opinion Leader Dr. David B. Hoyt. The event will cover intestinal barrier health and Palisade's targeted therapeutics for gastrointestinal complications. A live video webcast will be available on the company's investor page, with a replay accessible for 90 days.

LB1148, Palisade's lead asset, aims to reduce abdominal adhesions and restore bowel function post-surgery.

Palisade Bio, a clinical stage biopharmaceutical company focused on therapies for gastrointestinal complications, will participate in the 2022 Virtual Growth Conference from March 28-30, 2022. The conference, organized by Maxim Group LLC, offers a platform for multiple sectors, including Biotech and Healthcare. A video webcast of Palisade's presentation will be available on-demand. Notably, the company is advancing its lead asset, LB1148, which demonstrated promising results in Phase 2 trials and is set to enter Phase 3 in late 2022.

Palisade Bio, a clinical stage biopharmaceutical company, has received a "Study May Proceed" letter from the FDA for its Phase 3 trial of LB1148. This trial aims to evaluate LB1148's ability to accelerate bowel function recovery in patients after abdominal surgery. Approximately 600 subjects will be enrolled in this double-blinded, placebo-controlled study. Previous Phase 2 trials demonstrated LB1148's effectiveness in improving GI function and patient outcomes. Palisade plans to commence the trial in the latter half of 2022, highlighting LB1148's potential to benefit post-surgical patients significantly.

Palisade Bio, Inc. (Nasdaq: PALI) reported significant advancements in its clinical programs and financial results for the year ended December 31, 2021. The merger with Seneca and a $22 million financing provided essential capital to support clinical development. Positive Phase 2 results for LB1148 showed a 1.1-day acceleration in bowel function return after GI surgery, prompting progression to Phase 3 studies.

Furthermore, LB1148 received FDA Fast Track designation for treatment indications, enhancing its development prospects. As of year-end 2021, Palisade held $10.5 million in cash and reduced R&D expenses.

Palisade Bio, Inc. (Nasdaq: PALI) announced significant results from a pooled analysis of its studies on LB1148, a protease inhibitor aimed at reducing postoperative adhesions in bowel resection surgeries. The analysis demonstrated a 72% reduction in adhesion formation and 93% reduction in adhesion severity. Notably, the incidence of adhesions in the placebo group aligned with published rates of 89% and over 90%. LB1148 has received Fast Track designation from the FDA, highlighting its potential to address a critical unmet medical need. A conference call is scheduled for March 16, 2022.

Palisade Bio (Nasdaq: PALI) is presenting pivotal data on post-surgical intraabdominal adhesions at the upcoming SAGES 2022 Annual Meeting on March 16. The ePoster, titled "Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148," highlights the significant unmet medical need, with nearly 7 million surgeries annually in the U.S. and $2 billion spent on treatment. The company aims to demonstrate how LB1148 can address these complications and improve recovery outcomes.

Palisade Bio, Inc. (Nasdaq: PALI) announced its participation at the Biocom Global Life Science Partnering Conference on February 24, 2022, with CEO Tom Hallam presenting at 11:30 a.m. PT. The company is advancing its lead product candidate, LB1148, towards global Phase 3 studies aimed at restoring bowel function post-GI surgery. Positive Phase 2 trial results indicated safety and significant improvement in recovery time. The in-person conference will bring together key industry stakeholders at The Lodge at Torrey Pines, San Diego, fostering valuable partnerships.